Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

Trump administration funding cuts and dismantling of USAID force the focus to shift from elimination back to treatment.

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

A new twice-yearly antiviral injection that can prevent HIV is likely to be approved soon in Australia. Making it affordable ...

The approval of Yeztugo is a momentous step in improving PrEP options available for people vulnerable to contracting ...

The World Health Organization has added the variant, known formally as XFG, to its monitoring list. A dry, irritated throat ...

USAID has been present in Uganda for over sixty years. It has funded development in agriculture, education and research in ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

Nearly 12 million people could lose health care coverage if the bill gets passed and signed by Trump, while hospitals would be hit hard by Medicaid cuts.